AGIO
Agios Pharmaceuticals, Inc.
$36.97
+0.61
(+1.68%)
Mkt Cap
2.20B
Volume
968,881
52W Range
22.24-46
Sector
Healthcare
Beta
0.54
EPS (TTM)
-7.25
P/E Ratio
-3.82
Revenue (TTM)
66.05M
Rev Growth (5Y)
-2.8%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$132.64
Undervalued
strong signal
72.1% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.03M | 36.50M | 26.82M | 14.24M | 0 | 0 | 117.91M | 94.39M | 43.01M | 69.89M | 59.12M | 65.36M |
| Net Income | (412.78M) | 673.73M | (352.09M) | (231.80M) | 1.60B | (327.37M) | (411.47M) | (346.03M) | (314.67M) | (198.47M) | (117.73M) | (53.50M) |
| EPS | -7.12 | 11.86 | -6.33 | -4.23 | -6.36 | -4.74 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 |
| Free Cash Flow | (377.29M) | (391.53M) | (297.06M) | (314.36M) | (413.06M) | (304.87M) | (382.79M) | (311.41M) | (289.86M) | 28.65M | (97.11M) | (61.57M) |
| FCF / Share | -6.51 | -6.89 | -5.34 | -5.74 | -6.83 | -4.42 | -6.38 | -5.42 | -6.22 | 0.73 | -2.59 | -1.83 |
| Operating CF | (372.98M) | (389.84M) | (296.06M) | (309.48M) | (407.32M) | (290.76M) | (370.62M) | (304.42M) | (285.23M) | 38.56M | (76.95M) | (59.35M) |
| Total Assets | 1.30B | 1.66B | 937.12M | 1.24B | 1.44B | 852.95M | 890.74M | 858.46M | 614.40M | 619.09M | 420.06M | 491.90M |
| Total Debt | 62.02M | 56.99M | 72.00M | 85.66M | 97.09M | 105.20M | 113.66M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 89.13M | 76.25M | 88.20M | 139.26M | 203.13M | 127.44M | 80.93M | 805.42M | 567.75M | 573.56M | 375.91M | 14.03M |
| Book Value | 1.19B | 1.54B | 811.02M | 1.10B | 1.29B | 399.50M | 640.53M | 687.54M | 375.50M | 358.59M | 345.12M | 424.37M |
| Return on Equity | -0.35 | 0.44 | -0.43 | -0.21 | 1.24 | -0.82 | -0.64 | -0.50 | -0.84 | -0.55 | -0.34 | -0.13 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.75M | 19.97M | 12.88M | 12.46M | 8.73M | 10.73M | 8.96M | 8.62M | 8.19M | 7.10M | 7.40M | 6.71M |
| Net Income | (99.11M) | (108.04M) | (103.43M) | (112.02M) | (89.29M) | (96.52M) | 947.91M | (96.12M) | (81.55M) | (95.94M) | (91.32M) | (83.81M) |
| EPS | -1.69 | -1.85 | -1.78 | -1.93 | -1.55 | -1.69 | 16.65 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 |
| Free Cash Flow | (119.69M) | (97.33M) | (89.71M) | (78.00M) | (112.25M) | (134.13M) | (84.64M) | (72.75M) | (100.01M) | (72.72M) | (62.01M) | (66.75M) |
| FCF / Share | -2.04 | -1.67 | -1.54 | -1.35 | -1.95 | -2.35 | -1.49 | -1.28 | -1.77 | -1.30 | -1.11 | -1.20 |
| Operating CF | (118.92M) | (96.21M) | (88.15M) | (77.12M) | (111.49M) | (133.17M) | (84.22M) | (72.59M) | (99.87M) | (72.49M) | (61.64M) | (66.75M) |
| Total Assets | 1.18B | 1.30B | 1.39B | 1.47B | 1.56B | 1.66B | 1.79B | 773.06M | 849.71M | 937.12M | 1.01B | 1.09B |
| Total Debt | 35.74M | 40.21M | 44.52M | 48.76M | 52.94M | 56.99M | 60.83M | 64.62M | 68.35M | 72.00M | 75.50M | 78.95M |
| Cash & Equiv | 113.60M | 89.13M | 92.71M | 80.87M | 78.96M | 76.25M | 253.73M | 84.52M | 118.76M | 88.20M | 64.33M | 84.75M |
| Book Value | 1.11B | 1.19B | 1.28B | 1.37B | 1.47B | 1.54B | 1.63B | 660.51M | 743.92M | 811.02M | 886.84M | 964.24M |
| Return on Equity | -0.09 | -0.09 | -0.08 | -0.08 | -0.06 | -0.06 | 0.58 | -0.15 | -0.11 | -0.12 | -0.10 | -0.09 |
AGIO News
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
AGIO Shares Sink Nearly 7% After Scrapping the Tebapivat SCD Program
Agios Reports Neutral Sickle Cell Data, Decides To Stop Development
Agios Pharma to discontinue sickle cell disease treatment development
Agios Provides Update on Phase 2 Trial of Tebapivat in Sickle Cell Disease
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)